SCHEMBL5022047

SCHEMBL5022047

COc1cccc([C@H]2OC(=O)N[C@@H]2c2cccc(-c3csc(C)n3)c2)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 2/20 0.55
HTT P42858 2/20 0.42
LMNA P02545 2/20 0.42
RAB9A P51151 4/20 0.41
NPC1 O15118 3/20 0.41
ALDH1A1 P00352 3/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
HPGD P15428 1/20 0.41
HSD17B10 Q99714 1/20 0.41
RECQL P46063 2/20 0.41
MAPT P10636 2/20 0.41
TSHR P16473 1/20 0.41
CYP19A1 P11511 1/20 0.41
GAA P10253 1/20 0.41
GFER P55789 1/20 0.41
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
MAPK1 P28482 1/20 0.40
HCRTR1 O43613 1/20 0.40
HCRTR2 O43614 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13642086 0.91 GRM5 (0.52) GRM5
SCHEMBL5022011 0.91 GRM5 (0.52) GRM5
SCHEMBL10279150 0.85 GRM5 (0.58) GRM5HTTRAB9ANPC1ALDH1A1
SCHEMBL13642040 0.83 GRM5 (0.56) GRM5HTTRAB9ANPC1ALDH1A1
SCHEMBL5021739 0.83 GRM5 (0.69) GRM5HTTLMNARAB9ANPC1
SCHEMBL5021780 0.82 GRM5 (0.58) GRM5HTTRAB9ANPC1ALDH1A1
SCHEMBL5021657 0.82 GRM5 (0.57) GRM5HTTLMNARAB9ANPC1
SCHEMBL10279282 0.82 GRM5 (0.57) GRM5ALDH1A1HPGDKMT2A
SCHEMBL5021586 0.81 GRM5 (0.62) GRM5RAB9ANPC1SMN1; SMN2
SCHEMBL5021989 0.81 GRM5 (0.61) GRM5HTTRAB9ANPC1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120283264-A1 Oxazolidinones as Modulators of MGLUR5 BRISTOL-MYERS SQUIBB COMPANY 2012-11-08 US disclosed
WO-2012064603-A1 OXAZOLIDINONES AS MODULATORS OF MGLUR5 BRISTOL-MYERS SQUIBB COMPANY (US) 2012-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120283264-A1 Oxazolidinones as Modulators of MGLUR5 GRM5, GRIK5, GRM1 GRM5 1/4885HTT 3168/4885LMNA 4607/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.